Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857347 | 0.86 | HDAC8 (0.44) | HTR2ACYP1A2ALOX15CYP2C19ALOX5 | |
| SCHEMBL8164326 | 0.86 | HDAC8 (0.44) | HTR2ACYP1A2ALOX15CYP2C19ALOX5 | |
| SCHEMBL28830508 | 0.83 | HTR2A (0.34) | CYP2A6HTR2ACYP1A2ALOX15ALOX5 | |
| SCHEMBL28830511 | 0.83 | HTR2A (0.34) | CYP2A6HTR2ACYP1A2ALOX15ALOX5 | |
| SCHEMBL10833320 | 0.81 | TAAR1 (0.42) | HTR2ACNR1CNR2 | |
| SCHEMBL1241307 | 0.81 | CHRM2 (0.39) | HTR2ACYP1A2ALOX5SLC6A2SLC6A4 | |
| SCHEMBL11856343 | 0.80 | NR1I2 (0.37) | CYP1A2CYP2C19ALOX5 | |
| SCHEMBL19262248 | 0.80 | KMT2A (0.33) | HTR2ACYP1A2ALOX5CNR1 | |
| SCHEMBL15348656 | 0.78 | CYP2C19 (0.38) | HTR2ACYP1A2CYP2C19ALOX5 | |
| SCHEMBL1306565 | 0.77 | IGF1R (0.42) | CYP2A6HTR2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | CYP2A6 1209/4885HTR2A 1271/4885CYP1A2 646/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | CYP2A6 1218/4885HTR2A 950/4885CYP1A2 629/4885 |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | H1-0, H1-2, HDAC1 | CYP2A6 594/4885HTR2A 3040/4885CYP1A2 1183/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP2A6 1217/4885HTR2A 1263/4885CYP1A2 697/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | CYP2A6 1217/4885HTR2A 1263/4885CYP1A2 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.